Mylan Inc reports availibility of generic Tricor Tablets, 48 mg and 145 mg.
M2 EQUITYBITES-May 20, 2013-Mylan Inc reports availibility of generic Tricor Tablets, 48 mg and 145 mg(C)2013 M2 COMMUNICATIONS http://www.m2.com
Pharmaceutical company Mylan Inc (NasdaqGS:MYL) reported on Friday the shipment of Fenofibrate Tablets, 48 mg and 145 mg, following the final approval from the US Food and Drug Administration (FDA).
This shipment has been initiated by the company's subsidiary, Mylan Pharmaceuticals Inc.
The company said that the Fenofibrate Tablets, 48 mg and 145 mg are the generic version of Abbvie Inc's Tricor Tablets.
Fenofibrate Tablets are reportedly indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), Triglycerides and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia.
According to IMS Health, Fenofibrate Tablets, 48 mg and 145 mg, had US sales of approximately USD1.2bn for the 12 months ending 31 March 2013.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||May 20, 2013|
|Previous Article:||Norden and Harris CapRock extend agreement to add VSAT Communications Services to Norden's global fleet.|
|Next Article:||EnteroMedics Inc concludes its obesity VBLOC therapy Pre-PMA Meeting with the US FDA.|